Dey Pharma, L.P., a subsidiary of Mylan Inc. (MYL) said that it launched a newly designed, patient-friendly EpiPen Auto-Injector 0.3/0.15 mg and this next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several features, including being the only auto-injector with needle-protection before and after use.
EpiPen Auto-Injector is a prescribed first-line emergency auto-injector for potentially life-threatening allergic reactions known as anaphylaxis, and this can occur when people with allergies to food, insect stings, latex or other allergens come in contact with that allergen.
The company said that immediate access to epinephrine is critical during the first few minutes of an anaphylactic reaction.
Speaking about EpiPen and EpiPen Jr. Auto-Injectors, the company stated that it is for the emergency treatment of severe allergic reactions caused by allergens, exercise, or unknown triggers; and for patients who are at increased risk for these reactions.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.